. Author manuscript; available in PMC: 2012 Mar 19.

Published in final edited form as: J Am Acad Dermatol. 2009 Oct;61(4):677.e1–677.14. doi: 10.1016/j.jaad.2009.03.016

Table V.

Young age of melanoma diagnosis in nonfamilial setting does not warrant cyclin-dependent kinase inhibitor 2A testing

Study	Study location	Age criteria, y	MPM	Family history of melanoma	CDKN2A-positive
Whiteman et al,³¹ 1997	Australia (Queensland)	<15	nd	✓	1/10 (10%)
					0/21 (0%)
Tsao et al,²⁹ 2000	United States (Massachusetts)	<40	✓(4%)	✓	1/14 (7%)
					0/35 (0%)
Youl et al,²⁶ 2002	Australia (Queensland)	15–19	nd	nd^*	2/147 (1%)
Berg et al,²⁸ 2004	Sweden	<20	nd	✓	1/6 (17%)
					0/45 (0%)
Soufir et al,²⁵ 2004	France (Paris)	<25	nd	nd	0/21 (0%)
Nagore et al,²⁷ 2005	Spain (Valencia)	<31	✓(7.5%)	✓	2/6 (33%)
					0/34 (0%)
Stratigos et al,³⁰ 2006	Greece (Athens)	≤ 40			1/18 (6%)
Debniak et al,²⁴ 2008	Poland	≤ 40	nd	nd	0/72 (0%)

CDKN2A, Cyclin-dependent kinase inhibitor 2A; MPM, multiple primary melanoma; nd, not determined.

Two CDKN2A carriers did not have family history of melanoma among first-degree relatives.